Good Evening Reader,
Pull up (NASDAQ: CERO) now. Read below...
--
CERo Therapeutics Holdings, Inc.
CERo is an emerging immunotherapy company developing next-generation engineered T cell therapies for the treatment of cancer. Its proprietary Chimeric Engulfment Receptor (CER-T) technology integrates the most powerful elements of both innate and adaptive immunity, enabling T cells to directly attack and “engulf” tumor cells while simultaneously triggering a broad immune response. This dual-action mechanism allows CER-T cells to recognize “eat me” signals on tumor cells, destroy them through phagocytic activity, and then present tumor-associated antigens — potentially creating a sustained and systemic anti-tumor effect. CERo believes this differentiated biology may overcome the limitations of conventional CAR-T therapies, opening the door to broader therapeutic use across hematologic malignancies and solid tumors. CERo’s lead candidate, CER-1236, is currently in a Phase 1 clinical trial for acute myeloid leukemia (AML), where early safety and cell expansion data have been encouraging.
Most Notable Catalysts for CERO:
● October 22, 2025 – Maxim Growth Summit Panel
CEO Chris Ehrlich will participate in a stem cell therapy panel titled “A Space That is Ready to Have its Day” at the Maxim Growth Summit in New York City. The event, moderated by Jason McCarthy, Ph.D., Head of Biotechnology Research at Maxim Group, will take place at 1:30 p.m. ET at the Hard Rock Hotel.
● October 13, 2025 – Successful Completion of First Clinical Cohort
CERo announced the successful completion of the first cohort of its Phase 1 CER-1236 clinical trial for AML. No dose-limiting toxicities were observed, and cell expansion was consistent with preclinical expectations — a major early safety milestone. The company has begun dosing the second cohort, increasing the starting dosage while also exploring multiple-infusion strategies to optimize treatment response.
● U.S. and Japan Patent Expansions
CERo received a Notice of Allowance from the U.S. Patent and Trademark Office for Application 19/019,111, covering composition and use of CER-1236 to treat cancer through 2041. The company also received a new Japanese patent, bringing its IP portfolio to 18 issued patents and 2 allowed applications across key global markets.
● Additional Global Patent Strengthening
The USPTO granted two patents — including U.S. Patent No. 12,291,557 and a European allowance for Application No. 1882166.7 — covering the company’s CER-1236 design and chimeric receptor structure. These provide composition of matter protection and reinforce global exclusivity.
● Two More Patent Allowances from the USPTO
The USPTO allowed applications covering cellular immunotherapy compositions and CER design innovations, further broadening CERo’s IP protection to nine patent families extending through 2039 in the U.S.
